Start Submission Become a Reviewer

Reading: Evaluation of the antimetastatic and antitumor activity, of antibody loaded pemetrexed nanop...

Download

A- A+
Alt. Display

Experimental Research

Evaluation of the antimetastatic and antitumor activity, of antibody loaded pemetrexed nanoparticles, in DEN-HepG2 hepatocarcinoma model

Authors:

Shyam S. Agrawal,

Department of Pharmacology, Delhi Pharmaceutical Science and Research University, New Delhi, IN
About Shyam S.

PhD (AIIMS), DSc (RGPV-Bhopal), FISC, FIPS

X close

Namita Kaushik

Department of Pharmacology, Delhi Pharmaceutical Science and Research University, New Delhi 110017, IN
About Namita

MPharma (Pharmacology), BPharm (DIPSAR-DU)

X close

Abstract

Hepatocellular carcinoma (HCC) is the sixth highest incidence of cancer worldwide, accounting for 5.7% of the overall incident cases of cancer with the third leading cause of cancer-related deaths in all age group population. Matrix metalloproteinases play an important role in cancer progression, including tumor growth, invasion, metastasis, and angiogenesis, thus the drug delivery system targeting on MMP’s would be of good significance. This study aims evaluation of the antimetastatic and antitumor activity, of antibody loaded pemetrexed nanoparticles, in di-ethylnitrosamine-HepG2 hepatocarcinoma model. An orthotopic HCC model was prepared by using di-ethylnitrosamine-CCl4 as a precursor for liver cirrhosis and as carcinogen. Study concludes that the HCC model prepared was fast and equivalent to the other models present. The targeted nanoparticles prepared, has better efficacy profile with lower side effects then the free pemetrexed available in market. Low dose and high dose (20/25 mg)/kg of pemetrexed treats HCC significantly. Our results provide a basis for further study of targeted nanoparticles.

How to Cite: Agrawal SS, Kaushik N. Evaluation of the antimetastatic and antitumor activity, of antibody loaded pemetrexed nanoparticles, in DEN-HepG2 hepatocarcinoma model. International Journal of Surgery: Oncology. 2017;3(1):e48. DOI: http://doi.org/10.1097/IJ9.0000000000000048
3
Views
Published on 11 Dec 2017.
Peer Reviewed

Downloads

  • PDF (EN)